Nonalcoholic fatty liver disease - Test2 - elhamkhani - TriplyDB

Nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease

http://www.wikidata.org/entity/Q74069909

about

Nonalcoholic fatty liver disease

http://www.wikidata.org/entity/Q74069909

description

Nonalcoholic fatty liver disea ...... nd irreversible damage simi...

@en

name

Nonalcoholic fatty liver disease

@en

type

label

Nonalcoholic fatty liver disease

@en

prefLabel

Nonalcoholic fatty liver disease

@en

P1050

Q74069909-D34211A4-A5BF-43AA-BA9C-D278A5F58670

P1476

Q74069909-1E26905F-BF41-4DE4-9453-64F33BB488FB

P2093

Q74069909-8347C3AC-0934-49DA-A1C4-8D0D45A210D4

Q74069909-DC7E9B25-0814-4EC9-901A-69CE20CDE0B0

P2410

Q74069909-B76CAD78-9325-464B-ACF2-40D0F75893F0

P2860

Q74069909-0A438416-EBDB-41F9-A3CE-D0134AA076F1

Q74069909-2E4CEFFD-47A5-473D-B961-57E913C04CA1

Q74069909-32FCCA0B-E75A-4515-BB34-548AE4E4F251

Q74069909-80595464-E156-4D52-BBD7-53C1A6D5543F

Q74069909-83B8A2B7-A76C-40CE-A733-5AB86278C62E

Q74069909-929FEAA3-6749-4E59-816D-690EB750B916

Q74069909-965B52CD-60AA-4563-9896-DAF45B5D6425

Q74069909-9A9D5276-69A0-4E05-837D-BAFD05590532

Q74069909-AA5FD9BA-DFB1-4997-9BAC-9AA59D2475F6

Q74069909-B86FB408-01B5-415B-88EC-A2D8E3B6C2B5

P2888

Q74069909-E4403138-87C5-4CFA-A22F-A8BEFDFDF21C

P31

Q74069909-6DCA38AC-40AE-449F-AE1F-71714AF8A22F

P50

Q74069909-355BADD9-E228-4EAB-B248-D5A71E2F5ABA

Q74069909-55ACD22F-C333-4D8D-8640-312A153AC442

P527

Q74069909-0143B7E6-18D2-42C8-B7DF-90C513938660

Q74069909-01756512-1BF1-403E-86C7-4A482CFF9233

Q74069909-044876A3-BF37-4D1C-AAAB-A31856300131

Q74069909-064B003C-91EF-49AB-BBAB-A2BB9DC8CC81

Q74069909-0693E7C9-B09E-4F04-9F1B-BD80D1F04893

Q74069909-06BFE3C1-0EEE-4A65-A7BC-5C0F6737A4D1

Q74069909-08F0FAFD-8E65-41CB-965B-9AE46C726D49

Q74069909-0AD568FD-4B6A-49AB-8E0D-173975CB373E

Q74069909-0BB69A4B-23D9-483C-80E6-27CD77B6C054

Q74069909-0D2A32DC-294C-4806-9160-653ABA07D5C6

P703

Q74069909-FE24B3B1-7961-4FC6-8DD8-6E23BC3A22C2

P921

Q74069909-F2C318C8-16C0-45D5-98B7-C208EA7AD8D1

P1050

Non-alcoholic fatty liver disease

P1476

Nonalcoholic fatty liver disease

@en

P2093

Alexander Pico

http://www.w3.org/2001/XMLSchema#string

Egon Willighagen

http://www.w3.org/2001/XMLSchema#string

P2410

WP4396

http://www.w3.org/2001/XMLSchema#string

P2860

Endoplasmic reticulum stress and the inflammatory basis of metabolic disease

A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches

Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.

Endoplasmic reticulum stress in liver disease.

Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?

Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases.

Molecular mechanisms involved in NAFLD progression.

The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial.

Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis.

P2888

P31

biological pathway

P50

Egon Willighagen

Alexander R. Pico

P527

P703

P921

disease pathway